News | January 21, 2023
Marksans Pharma raises Rs. 372.40 crores
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Plans to double its manufacturing footprint to bolster the growth
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
Subscribe To Our Newsletter & Stay Updated
